Company: PCRX
Filing Date: 2025-03-14
Form Type: DEFA14A
Source: 0001104659-25-024033
Chunk: 6

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DEFA14A
Chunk 6
---
5. Details concerning potential participants in the solicitation, including Pacira’s director nominees for election at the 2025 Annual Meeting, will also be included in the 2025 Proxy Statement. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC ,are, or will be when filed, available for no charge on the SEC’s website at http://www.sec.govand on Pacira’s investor relations website at https://investor.pacira.com.

On March 14, 2025, Pacira BioSciences, Inc. sent the following note to employees:

Subject: FYI: Pacira taking decisive action to enhance shareholder value

Please take a moment to read the note below, sent on behalf of Frank D. Lee

+++++++++

Dear Pacira Team,

Pacira’s Board and Management Team are taking decisive action
to enhance shareholder value. We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver
shareholder value. We are confident that we are well positioned to accelerate growth and continue executing our long-term strategy.

As you may have seen, DOMA, an asset management firm that is a Pacira
shareholder, issued a press release announcing the nomination of three candidates to our Board of Directors for our 2025 Annual Meeting
of Stockholders. The Nominating, Governance and Sustainability Committee of our Board will evaluate and consider DOMA’s proposed
candidates, as it does with all director candidates.

Thanks to your hard work, we are already making strong strides against
our 5x30 strategy, including:

| 1. | Solid                                                                                                                             
 progress across our commercial portfolio while continuing to meet guidance, as evidenced by the strong Q4 2024 financial results; |

| 2. | Important                                                                                                                                      
 acquisitions, like our recent GQ Bio transaction, toward long-term value creation as we evolve toward becoming an innovative biopharmaceutical 
 organization and a leading developer of new treatments for musculoskeletal pain and adjacencies by addressing the underlying cause of          
 chronic pain using a targeted molecular approach;                                                                                              |

| 4. | Executing                                                                                                                           
 against our refreshed mission alongside our revised guiding principles and core values, which serve as the fabric of our ONE Pacira 
 culture.                                                                                                                            |

As we look ahead, I’m confident that we have the right team
and the right strategy in place to build on the momentum underway